

JUL 13 2004

OFFICIAL

Merchant & Gould

An Intellectual Property Law Firm

3200 IDS Center
80 South Eighth Street
Minneapolis, Minnesota
55402-2215 USA
TEL 612.332.5300
FAX 612.332.9081
www.merchant-
gould.com

A Professional Corporation

Fax Transmission | July 13, 2004

TO: Commissioner for Patents
Attn: Examiner Unassigned
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: Anna M. Nelson

OUR REF: 12152.15USC6
TELEPHONE: 612.336.4701

Total pages, including cover letter: 6

PTO FAX NUMBER 1-703.872.9306

If you do NOT receive all of the pages, please telephone us at 612.371.5394, or fax us at 612.332.9081.

Title of Document Transmitted: Preliminary Amendment
Applicant: Uckun et al.
Serial No.: 10/726,073
Filed: December 1, 2003
Group Art Unit: 1623
Our Ref. No.: 12152.15USC6
Confirmation No. 2559

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: Anna M. Nelson
Name: Anna M. Nelson
Reg. No.: 48,935

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Victoria Hanson
Signature

July 13, 2004
Date

GEN033.DOT

JUL 13 2004

OFFICIAL

S/N 10/726,073

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Uckun	Examiner:	UNKOWN
Serial No.:	10/726,073	Group Art Unit:	1623
Filed:	December 1, 2003	Docket No.:	12152.15USC6
Title:	Aryl Phosphate Derivatives of d4T Having Anti-HIV Activity		
Customer No.:	23552	Confirmation No.:	2559

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 703.872.9306 on July 13, 2004.

By:

Name: Victoria Hanson

PRELIMINARY AMENDMENT

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Prior to examination, please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 5 of this paper.